Tag: Alterity Therapeutics
Phase-II of the ATH434 trial for multiple system atrophy patient dosing has started, according to Alterity Therapeutics.
The first participant in Alterity Therapeutics’ phase 2 clinical trial of ATH434 in multiple system atrophy (MSA), a…
